Cystic Fibrosis
Cystic Fibrosis (CF) is a rare genetic disorder inherited in an autosomal recessive manner, primarily characterized by thick and sticky mucus that clogs the lungs, leading to breathing problems, frequent lung infections, and complications in multiple organs including the pancreas, liver, intestines, and sex organs. It manifests through symptoms such as difficulty breathing, coughing up mucus, sinus infections, poor growth, fatty stool, clubbing of fingers and toes, and infertility in most males.
Health Outcomes
- Additional Therapeutic Benefits
- Adjusted Height-for-Age Z Score
- Altered Hydrophobicity
- Altered Intestinal Transit
- Altered Microbial Profile
- Colonization of Nasopharynx or Adenoid Tissue
- Decreased Mannitol Flux
- Decreased Oxygen Saturation
- Decreased Peripheral CD3⁺ T Lymphocyte Count
- Dispersed Pathogenic Biofilms
- Enhanced Antioxidant Capabilities
- Enhanced Bactericidal Activity
- Enhanced Beneficial Metabolite Production
- Enhanced Goblet Cell Function
- Enhanced Growth Performance
- Enhanced Growth Rate
- Enhanced Growth and Development
- Enhanced Host-Microbe Balance
- Enhanced Influenza Resistance
- Enhanced Nutrient Bioavailability
- Enhanced Phagocytic Capacity of Mononuclear Phagocytes
- Enhanced Protection Against Influenza Infection
- Enhanced Pulmonary Immune Response
- Enhanced Resistance to Bacterial Infections
- Enhanced Resistance to Streptococcus Pneumoniae Infection
- Enhanced Serum-Mediated E. coli Killing
- Equivalence in Growth Parameters
- Healthy Age-Appropriate Growth
- Improved Absorption of Essential Trace Elements
- Improved Aerobic to Anaerobic Bacteria Ratio
- Improved Airway Mucosa Condition
- Improved Airway Secretion Clearance
- Improved Amino Acid Absorption
- Improved Amino Acid Bioavailability
- Improved Amino Acid Composition
- Improved Amino Acid Profile
- Improved Anaerobic Power
- Improved Apparent Digestibility of Crude Protein
- Improved Bioavailability
- Improved Biofilm Development
- Improved Cell Survival Rates
- Improved Cellular Immune Response
- Improved Clearance Efficiency
- Improved Colonization Efficiency
- Improved Deep Lung Delivery Feasibility
- Improved Digestibility of Amino Acids
- Improved Effectiveness in Cystic Fibrosis Treatment
- Improved Emulsification Properties
- Improved Enteral Nutrition Achievement Time
- Improved Environmental Stress Tolerance
- Improved Enzyme Activity
- Improved FEV1
- Improved Forced Vital Capacity
- Improved Functional Properties of Food
- Improved Growth
- Improved Growth Indices
- Improved Growth Metrics
- Improved Growth Metrics Stability
- Improved Growth and Economic Traits
- Improved Growth in Children
- Improved Gut Microbiota Colonization
- Improved Histopathological Findings in Lungs
- Improved Immune Mechanisms Against S. pneumoniae
- Improved Infant Gut Health
- Improved Influenza Infection Control
- Improved Intestinal Transit
- Improved JMCIS Score
- Improved Lipase Activity
- Improved Lung Barrier Function
- Improved Lung Function
- Improved Mucus Binding
- Improved Neutrophil Function
- Improved Nutrient Absorption
- Improved Nutrient Absorption and Metabolism
- Improved Nutrient Digestibility
- Improved Nutrient Retention
- Improved Nutritional Content
- Improved Oxygenation Index
- Improved Pancreatic Tissue Repair
- Improved Parent/Caregiver Quality of Life
- Improved Pathogen Tolerance
- Improved Phagocytic Capacity of Polymorphonuclear Cells
- Improved Protein Absorption
- Improved Protein Digestion
- Improved Protein Hydrolysis Capacity
- Improved Protein Utilization
- Improved Pulmonary Function
- Improved Resistance to Secondary Pneumococcal Pneumonia
- Improved Respiratory Immune Function
- Improved Respiratory Mucosal Barrier Function
- Improved Respiratory Tract Health
- Improved Specific Growth Rate
- Improved Survival Rate After Bacterial Challenge
- Improved Swimming Performance
- Improved Symptoms of Chronic Condition
- Improved VO2 Max
- Improved Vitamin A Content
- Improved Weight Percentile
- Improved Zinc Absorption
- Increased Abundance of Goblet Cells
- Increased Deoxygenated Hemoglobin Level
- Increased Digestible Energy
- Increased Endogenous Bacteria
- Increased Excretion of Acidic Steroids in Feces
- Increased Exopolysaccharide Production
- Increased Expression of Beta-Defensin 3
- Increased Expression of Human Beta Defensin-2
- Increased Fecal Cell Persistence
- Increased Fecal Energy Excretion
- Increased Goblet Cell Count
- Increased Goblet Cell Differentiation
- Increased Incidence of Pulmonary Exacerbations
- Increased Infection
- Increased Infection Frequency
- Increased Interleukin 8 Levels
- Increased Intestinal Lactobacillus sakei Levels
- Increased MUC-2 Levels
- Increased Maximal Incremental Cycling Capacity
- Increased Mucin Production
- Increased Mucin Secretion
- Increased Mucus Binding Capacity
- Increased Mucus Enzyme Activities in Skin
- Increased Mucus Secretion
- Increased Oxalate-Degrading Activity
- Increased Production of Antimicrobial Peptides
- Increased Protease Levels
- Increased Protein Digestibility
- Increased Risk of Opportunistic Pathogenicity
- Increased Serum Amylase Activity
- Increased Serum Lysozyme Activity
- Increased Serum Macrophage Inflammatory Protein-1β Levels
- Increased Skin Mucus Antibacterial Activity
- Increased Skin Mucus Protein Levels
- Increased TIMP-1 Levels
- Increased Time to Exhaustion
- Increased Time to Ventilatory Threshold
- Increased Total Bacterial Abundance
- Increased Transforming Growth Factor-β Levels
- Increased Viable Cell Antioxidant Activity
- Inhibited Digestive Enzyme Activity
- Maintained Bacterial Diversity
- Maintained Barrier Function
- Maintained Growth Curve
- Maintained Growth Performance
- Managed Cystic Fibrosis
- No Change in Newborn Growth
- No Effect on Clostridioides difficile Colonization
- No Improvement in Growth Performance
- No Significant Change in Inflammatory Responses
- No Significant Differences in Growth
- Normal Growth Performance
- Normal Growth Performance and Hematological Parameters
- Occurrence of Necrotising Pneumonia
- Persistent Nasal Colonization
- Preserved Anti-pseudomonal Activity
- Prevention of Mucus Barrier Decline
- Probiotic-Related Infection
- Prolonged Survival Time in Influenza Infection
- Protection Against Cellular Damage Induced by Pathogens
- Reduced Adhesion of Enterococcus faecalis
- Reduced Adipose Tissue Wasting
- Reduced Airway Inflammation
- Reduced Alpha-Amylase Activity
- Reduced Amylase Level
- Reduced Anaerobic Gram-Negative Bacterial Counts
- Reduced Anthropometric Parameters
- Reduced Average Daily Gain
- Reduced Bacterial Infection Rates
- Reduced Bacterial Infection Severity
- Reduced Bacterial Load in Lungs
- Reduced Bacterial Translocation
- Reduced Bacterial Translocation to Mesenteric Lymph Nodes
- Reduced Baseline IL-8 Secretion
- Reduced Bile Acid Reabsorption
- Reduced CRKP Colonization
- Reduced Campylobacter jejuni Colonization/Growth
- Reduced Cell Growth Rate
- Reduced Chloride Level
- Reduced Common Cold Incidence in Susceptible Populations
- Reduced Copper Level
- Reduced Disease Severity
- Reduced Eosinophils in Bronchoalveolar Lavage Fluid
- Reduced Expression of Pro-Inflammatory Cytokines in Lung
- Reduced Fat Weight
- Reduced Fecal Bile Acid Levels
- Reduced Fecal Cholic Acid Increase
- Reduced Frequency of Upper Respiratory Tract Infections
- Reduced GAS Adherence to Host Epithelial Cells
- Reduced Glucose Absorption
- Reduced Growth Decline After Infection
- Reduced Growth Performance
- Reduced Growth of Harmful Bacteria
- Reduced Histopathological Damage
- Reduced Hydrogen Peroxide Concentration
- Reduced Hypoxia
- Reduced ICU Length of Stay
- Reduced IL-8 Production
- Reduced Incidence of Bacterial Pneumonia
- Reduced Incidence of Influenza
- Reduced Indigenous Enterobacteria Colonization
- Reduced Infection Frequency
- Reduced Inflammation in the Lower Respiratory Tract
- Reduced Interleukin-8 Levels
- Reduced Lung Damage
- Reduced Lung Inflammation
- Reduced Lung Injury
- Reduced Lung Neutrophils
- Reduced Lung Tissue Damage
- Reduced Lung Viral Proliferation
- Reduced Methane Metabolism
- Reduced Mortality from Influenza Infection
- Reduced Mucin Adhesion
- Reduced Mucin Gene Transcription
- Reduced Mucus Layer Thinning
- Reduced Opportunistic Pathogenic Bacteria Levels
- Reduced Oxidative Damage
- Reduced Oxidative Tissue Injury
- Reduced Oxidized Glutathione Level
- Reduced PICU Discharge Time
- Reduced Pancreatic Bacterial Penetration
- Reduced Pathogen Inhibition (e.g. Salmonella Species)
- Reduced Pathogen Resistance
- Reduced Pathogenic Bacterial Activity
- Reduced Pathogenic Bacterial Motility
- Reduced Pathogenic Colonies
- Reduced Pathogenic Microorganism Activity
- Reduced Peak Inspiratory Pressure
- Reduced Pediatric Exacerbations
- Reduced Pediatric Intensive Care Unit Stay
- Reduced Phagocytic Activity
- Reduced Plasma IgG Production
- Reduced Plasma Vitamin K Levels
- Reduced Pneumococcal Adherence
- Reduced Postprandial Insulin Response
- Reduced Pro-inflammatory Cytokine Release
- Reduced Proportion of Pathogenic Genera
- Reduced Proteolysis
- Reduced Pseudomonas Levels
- Reduced Pseudomonas aeruginosa Lung Infection Burden
- Reduced Pseudomonas aeruginosa-Induced Damage
- Reduced Pseudomonas in Feces
- Reduced Pulmonary Exacerbations
- Reduced Pulmonary Fibrosis
- Reduced Pulmonary Inflammation
- Reduced Respiratory Burst Activity
- Reduced Respiratory Illness
- Reduced Respiratory Inflammation Severity
- Reduced Respiratory Symptoms
- Reduced Risk of Obesity
- Reduced Risk of Prolonged Respiratory Infections
- Reduced S. aureus Cell Count In Vivo
- Reduced Serum Endotoxin Level
- Reduced Serum Ferritin Levels
- Reduced Severe Necrotizing Enterocolitis (NEC)
- Reduced Severity of Acute Respiratory Infection
- Reduced Severity of Influenza Infection
- Reduced Sitosterol Absorption
- Reduced Staphylococcus aureus Colonization
- Reduced Streptococcus pneumoniae in Lung
- Reduced Survival of Listeria innocua
- Reduced Susceptibility to Bacterial Infection
- Reduced Susceptibility to Pneumococcal Infection
- Reduced Time to Maximum Amino Acid Concentration
- Reduced Total Cells in Bronchoalveolar Lavage Fluid
- Reduced Upper Respiratory Infections
- Reduced Urinary Oxalate Excretion
- Reduced Villus Height
- Reduced Vitamin E Level
- Reduced Weight Gain and Fat Mass
- Regulated Interleukin 8 Levels
- Resolved Keratomalacia
- Restored Goblet Cell Count
- Restored Goblet Cell Function
- Restored Mucus Layer Integrity
- Stabilized Amino Acid Metabolism
- Unchanged Fecal Antibiotic Resistance
- Unchanged Growth Parameters